dimethyl fumarate mylan
mylan ireland limited - dimethylfumarat - multipel sklerose, recidiverende-remitterende - immunosuppressiva - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimethylfumarat - multipel sklerose, recidiverende-remitterende - immunosuppressiva - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimethylfumarat - multipel sklerose, recidiverende-remitterende - immunosuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
fampridin "axiromed" 10 mg depottabletter
medical valley invest ab - fampridine - depottabletter - 10 mg
dimethyl fumarate "sandoz" 120 mg enterokapsler, hårde
sandoz a/s - dimethylfumarat - enterokapsler, hårde - 120 mg
dimethyl fumarate "sandoz" 240 mg enterokapsler, hårde
sandoz a/s - dimethylfumarat - enterokapsler, hårde - 240 mg
dimethyl fumarate teva
teva gmbh - dimethylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate accord
accord healthcare s.l.u. - dimethylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
fampridine "newbury" 10 mg depottabletter
newbury pharmaceuticals ab - fampridine - depottabletter - 10 mg
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.